– 19 Abstracts Will Feature the Latest Advances in the Company’s HIV, COVID-19 and Viral Hepatitis Research Programs –
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021) taking place from March 6-10. The breadth of data at the meeting reflects Gilead’s longstanding commitment to applying its scientific innovation toward addressing some of the world’s most challenging viruses and advancing global health.
“The impact of COVID-19 on its own has been devastating for public health, and the disruption to the healthcare system and worsening health inequity driven by the pandemic are threatening to set back efforts to end the HIV epidemic and the hard-won progress toward HCV elimination,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. “Now more than ever, there is an urgent need to accelerate and advance innovative antiviral research to help prevent transmission and provide a portfolio of therapeutic options for those affected. The data we will present at CROI 2021 demonstrate the important scientific advancements we have made to help address the needs of people living with HIV and HCV, and those affected by COVID-19.”
HIV Research
At CROI 2021, Gilead will share new findings on daily and long-acting HIV prevention and treatment strategies, as well as updates from the company’s continued pursuit of a cure for HIV.
Data will include Phase 2/3 CAPELLA trial results evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in heavily treatment-experienced people with multidrug resistant HIV-1 infection. The company will also present data from a pre-clinical study evaluating lenacapavir for HIV pre-exposure prophylaxis (PrEP).
Insights from Gilead’s cure research program include new data on vesatolimod, an investigational toll-like receptor 7 (TLR7) agonist, as well as analyses of analytical treatment interruption studies using mathematical modelling techniques and approaches for assessing broadly neutralizing antibodies (bNAbs) sensitivity.
HIV treatment research includes long-term data from two Phase 3 studies (Study 1489 and Study 1490) that demonstrated the safety and efficacy profile of the once-daily, single tablet regimen, Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) compared with dolutegravir (DTG)-containing regimens for the treatment of HIV-1 infection in treatment-naïve adults. The data include a sub-analysis in participants with certain transmitted drug resistance and cumulative outcomes from an open-label extension (OLE) phase of two Phase 3 studies evaluating treatment outcomes in participants who initiated therapy with Biktarvy and those who switched to Biktarvy from a DTG-containing regimen.
HCV Research
Results from the ACTG A5360 Study will be presented on the minimal monitoring (MINMON) approach to HCV treatment with Epclusa® (400 mg sofosbuvir/100 mg velpatasvir) across a range of settings and in key populations most impacted by the virus.
Please refer to the full Prescribing Information for complete monitoring information for Epclusa.
COVID-19 Research
Gilead will also present preliminary data from the ongoing Phase 2/3 CARAVAN study evaluating the safety and efficacy of Veklury® (remdesivir) for the treatment of hospitalized pediatric patients two months to 17 years of age. Additional data from an open-label, Phase 3 trial evaluating Veklury's impact on kidney function in patients with moderate COVID-19 will also be presented. Veklury is the only approved antiviral for the treatment of COVID-19.
Select accepted abstracts are as follows:
Investigational Long-Acting HIV Research (Lenacapavir) |
Potent Antiviral Activity of Lenacapavir in Phase 2/3 in Heavily ART-experienced PWH |
Long-acting HIV Capsid Inhibitor Effective as PrEP in a SHIV Rhesus Macaque Model |
Clinical Evaluation of Drug Interactions With Oral Lenacapavir and Probe Drugs |
Activity and Resistance Characterization of the HIV Capsid Inhibitor Lenacapavir |
Pharmacokinetics of Lenacapavir, an HIV-1 Capsid Inhibitor, in Hepatic Impairment |
HIV Treatment Research |
Four-Year Outcomes of B/F/TAF in Treatment-Naïve Adults |
HIV With Transmitted Drug Resistance is Durably Suppressed by B/F/TAF at Week 144 |
HIV-1 DNA Genotyping is Often Variable in Repeat Testing From Single Blood Draws |
Drug Interactions With Once-Daily B/F/TAF in Combination With Once-Weekly Rifapentine |
HIV Prevention Research |
Ultrasensitive HIV-1 Drug-Resistance Analysis in the DISCOVER PrEP Trial |
HIV Cure Research |
Mathematical Modeling of Predictors of Posttreatment Control in HIV Cure Trials |
HIV Rebound in Controllers is Associated With Specific Fecal Microbiome Profile |
Evaluation of bNAb Sensitivity by Genotyping and Phenotyping for HIV Clinical Trials |
Activating PKC-ε Induces HIV Expression With Improved Tolerability |
COVID-19 Research |
Safety and Efficacy of Remdesivir in a Pediatric COVID-19 Population |
Treatment and Outcomes of COVID-19 in the U.S.: Are They Different According to Race? |
Acute Kidney Injury in Patients With Moderate COVID-19 Treated With Remdesivir Versus SoC |
Remdesivir Versus Standard of Care for Severe COVID-19 |
HCV Research |
A Simple and Safe Approach to HCV Treatment: Findings From the A5360 (MINMON) Trial |
For more information, including a complete list of abstracts, click here.
Please see below for U.S. Indications and Important Safety Information, including Boxed Warnings, for Biktarvy®, Descovy®, Descovy for PrEP®, and Epclusa®. Please also see below for U.S. Indication and Important Safety Information for Veklury®.
Lenacapavir and vesatolimod are investigational compounds and are not approved by the U.S. Food and Drug Administration or any other regulatory authority for any use. Their safety and efficacy are unknown. In May 2019, FDA granted Breakthrough Therapy Designation for the development of lenacapavir for the treatment of HIV-1 infection in heavily treatment-experienced patients with multi-drug resistance.
The use of Biktarvy in individuals with known resistance to the components of Biktarvy is investigational, and the safety and efficacy of Biktarvy for this use have not been established.
There is no cure for HIV or AIDS.
U.S. Important Safety Information for Biktarvy
BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
Contraindications
Warnings and precautions